VENTURE (12+ years)¹²

DUPIXENT reduced or eliminated steroids while simultaneously improving more than one measure of asthma control (ie, reduced severe exacerbation rates and improved lung function) at Week 24 in the ITT population (no biomarker requirement, VENTURE, secondary endpoints).^1,12

• 86% of patients reduced or eliminated their OCS dose at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107)¹²
  • A 70% significant reduction in OCS dose (median 100%) from baseline was observed at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)¹
• A 59% reduction in severe exacerbations was seen at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63])^1,k
• A 220 mL improvement in lung function was achieved at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90, 340 mL])¹²